Biomarkers in rare diseases

A. Ferlini, C. Scotton, G. Novelli

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Nowadays 7,000 rare diseases (RDs) have been identified with a prevalence less than 5/10,000. Despite of the enormous effort the European Union (EU) has already invested in this field, still 4,000 RDs remain orphan of genetic diagnosis and causative gene identification. The genetic definition of RDs represents a prerequisite for being diagnosed, for having a robust prevention, for entering in a specific standard of care, and ultimately, for being included in clinical trials, often via personalized medicine. It is well established that biomarkers can offer a way to speed up research by understanding the pathophysiological mechanisms of diseases. In particular, biomarkers will offer an invaluable tool for monitoring disease progression, prognosis and response to drug treatment. Methods: In this review, we summarize the different types of biomarkers and their importance as well as their translational applications in RDs. We have reviewed the current knowledge on biomarkers state-of-the-art via literature data, specific websites and EU sources regarding past, pending and current projects. Results: Here we provide a comprehensive scenario of biomarkers research, its applications in clinical practice, with special emphasis on translational research applicable to diagnostic and clinical trials. The experience of the EU project BIO-NMD is also mentioned. Conclusion: Biomarkers represent key features in both diagnostics and research on rare diseases and will encounter wide exploitation in translational and personalized medicine.

Original languageEnglish
Pages (from-to)313-321
Number of pages9
JournalPublic Health Genomics
Volume16
Issue number6
DOIs
Publication statusPublished - Apr 20 2013

Fingerprint

Rare Diseases
Biomarkers
European Union
Precision Medicine
Translational Medical Research
Research
Clinical Trials
Standard of Care
Disease Progression
Pharmaceutical Preparations
Genes

Keywords

  • Biomarkers
  • Diagnostics
  • Genetics
  • Genomics
  • Mendelian
  • Omics
  • Proteomics
  • Rare diseases
  • Therapies
  • Transcriptomics

ASJC Scopus subject areas

  • Genetics(clinical)
  • Public Health, Environmental and Occupational Health

Cite this

Ferlini, A., Scotton, C., & Novelli, G. (2013). Biomarkers in rare diseases. Public Health Genomics, 16(6), 313-321. https://doi.org/10.1159/000355938

Biomarkers in rare diseases. / Ferlini, A.; Scotton, C.; Novelli, G.

In: Public Health Genomics, Vol. 16, No. 6, 20.04.2013, p. 313-321.

Research output: Contribution to journalArticle

Ferlini, A, Scotton, C & Novelli, G 2013, 'Biomarkers in rare diseases', Public Health Genomics, vol. 16, no. 6, pp. 313-321. https://doi.org/10.1159/000355938
Ferlini A, Scotton C, Novelli G. Biomarkers in rare diseases. Public Health Genomics. 2013 Apr 20;16(6):313-321. https://doi.org/10.1159/000355938
Ferlini, A. ; Scotton, C. ; Novelli, G. / Biomarkers in rare diseases. In: Public Health Genomics. 2013 ; Vol. 16, No. 6. pp. 313-321.
@article{ee873c1c460b41a8903466cc2dcf06f9,
title = "Biomarkers in rare diseases",
abstract = "Background: Nowadays 7,000 rare diseases (RDs) have been identified with a prevalence less than 5/10,000. Despite of the enormous effort the European Union (EU) has already invested in this field, still 4,000 RDs remain orphan of genetic diagnosis and causative gene identification. The genetic definition of RDs represents a prerequisite for being diagnosed, for having a robust prevention, for entering in a specific standard of care, and ultimately, for being included in clinical trials, often via personalized medicine. It is well established that biomarkers can offer a way to speed up research by understanding the pathophysiological mechanisms of diseases. In particular, biomarkers will offer an invaluable tool for monitoring disease progression, prognosis and response to drug treatment. Methods: In this review, we summarize the different types of biomarkers and their importance as well as their translational applications in RDs. We have reviewed the current knowledge on biomarkers state-of-the-art via literature data, specific websites and EU sources regarding past, pending and current projects. Results: Here we provide a comprehensive scenario of biomarkers research, its applications in clinical practice, with special emphasis on translational research applicable to diagnostic and clinical trials. The experience of the EU project BIO-NMD is also mentioned. Conclusion: Biomarkers represent key features in both diagnostics and research on rare diseases and will encounter wide exploitation in translational and personalized medicine.",
keywords = "Biomarkers, Diagnostics, Genetics, Genomics, Mendelian, Omics, Proteomics, Rare diseases, Therapies, Transcriptomics",
author = "A. Ferlini and C. Scotton and G. Novelli",
year = "2013",
month = "4",
day = "20",
doi = "10.1159/000355938",
language = "English",
volume = "16",
pages = "313--321",
journal = "Public Health Genomics",
issn = "1662-4246",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Biomarkers in rare diseases

AU - Ferlini, A.

AU - Scotton, C.

AU - Novelli, G.

PY - 2013/4/20

Y1 - 2013/4/20

N2 - Background: Nowadays 7,000 rare diseases (RDs) have been identified with a prevalence less than 5/10,000. Despite of the enormous effort the European Union (EU) has already invested in this field, still 4,000 RDs remain orphan of genetic diagnosis and causative gene identification. The genetic definition of RDs represents a prerequisite for being diagnosed, for having a robust prevention, for entering in a specific standard of care, and ultimately, for being included in clinical trials, often via personalized medicine. It is well established that biomarkers can offer a way to speed up research by understanding the pathophysiological mechanisms of diseases. In particular, biomarkers will offer an invaluable tool for monitoring disease progression, prognosis and response to drug treatment. Methods: In this review, we summarize the different types of biomarkers and their importance as well as their translational applications in RDs. We have reviewed the current knowledge on biomarkers state-of-the-art via literature data, specific websites and EU sources regarding past, pending and current projects. Results: Here we provide a comprehensive scenario of biomarkers research, its applications in clinical practice, with special emphasis on translational research applicable to diagnostic and clinical trials. The experience of the EU project BIO-NMD is also mentioned. Conclusion: Biomarkers represent key features in both diagnostics and research on rare diseases and will encounter wide exploitation in translational and personalized medicine.

AB - Background: Nowadays 7,000 rare diseases (RDs) have been identified with a prevalence less than 5/10,000. Despite of the enormous effort the European Union (EU) has already invested in this field, still 4,000 RDs remain orphan of genetic diagnosis and causative gene identification. The genetic definition of RDs represents a prerequisite for being diagnosed, for having a robust prevention, for entering in a specific standard of care, and ultimately, for being included in clinical trials, often via personalized medicine. It is well established that biomarkers can offer a way to speed up research by understanding the pathophysiological mechanisms of diseases. In particular, biomarkers will offer an invaluable tool for monitoring disease progression, prognosis and response to drug treatment. Methods: In this review, we summarize the different types of biomarkers and their importance as well as their translational applications in RDs. We have reviewed the current knowledge on biomarkers state-of-the-art via literature data, specific websites and EU sources regarding past, pending and current projects. Results: Here we provide a comprehensive scenario of biomarkers research, its applications in clinical practice, with special emphasis on translational research applicable to diagnostic and clinical trials. The experience of the EU project BIO-NMD is also mentioned. Conclusion: Biomarkers represent key features in both diagnostics and research on rare diseases and will encounter wide exploitation in translational and personalized medicine.

KW - Biomarkers

KW - Diagnostics

KW - Genetics

KW - Genomics

KW - Mendelian

KW - Omics

KW - Proteomics

KW - Rare diseases

KW - Therapies

KW - Transcriptomics

UR - http://www.scopus.com/inward/record.url?scp=84899907896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899907896&partnerID=8YFLogxK

U2 - 10.1159/000355938

DO - 10.1159/000355938

M3 - Article

C2 - 24503592

AN - SCOPUS:84899907896

VL - 16

SP - 313

EP - 321

JO - Public Health Genomics

JF - Public Health Genomics

SN - 1662-4246

IS - 6

ER -